MYRIAD GENETICS INC. - COMMON STOCK

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

22 фев 2023 06:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics to Participate in Upcoming Healthcare Conferences

09 фев 2023 06:15:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

07 фев 2023 06:15:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

05 янв 2023 06:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

04 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

19 дек 2022 15:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

08 дек 2022 18:15:00 Источник Nasdaq GlobeNewswire

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

29 ноя 2022 15:05:00 Источник Nasdaq GlobeNewswire

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

17 ноя 2022 06:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

14 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

10 ноя 2022 07:00:03 Источник Nasdaq GlobeNewswire

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

03 ноя 2022 17:00:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

01 ноя 2022 08:10:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Reports Third Quarter Financial Results

01 ноя 2022 08:05:01 Источник Nasdaq GlobeNewswire

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

31 окт 2022 15:30:00 Источник Nasdaq GlobeNewswire

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

26 окт 2022 15:05:00 Источник Nasdaq GlobeNewswire

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

28 сен 2022 08:00:01 Источник Nasdaq GlobeNewswire

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

25 авг 2022 15:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe

16 авг 2022 00:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Reports Second Quarter Financial Results

04 авг 2022 06:05:01 Источник Nasdaq GlobeNewswire